May 07 2024 16 mins 3
In this podcast, Dr Edgar Lerma and Dr Dana Rizk discuss IgA nephropathy and the key data on sparsentan from the phase 3 PROTECT trial.
IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option
1.0x
00:00
00:00
